Title: Compositions and Methods for Inhibiting Expression of the Myc Gene
Patent Number: 8,124,752
Filed: July 9, 2007
Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals
The invention, the patent's abstract states, relates to “a double-stranded ribonucleic acid for inhibiting the expression of the Myc gene.”
The dsRNA comprises “an antisense strand having a nucleotide sequence ... less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of the Myc gene,” it adds. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Myc gene expression; and the expression of the Myc gene using the pharmaceutical composition.”
Title: Double-Stranded Nucleic Acid Molecule Cancer Cell Proliferation Inhibitor and Pharmaceutical Agent Suitable for Prevention or Treatment of Uterine Cancer, Breast Cancer, and Bladder Cancer
Patent Number: 8,124,754
Filed: Dec. 21, 2009
Lead Inventor: Satoshi Inoue, RNAi Co.
The patent, its abstract states, claims a “double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes.”
Title: Compositions and Methods for Inducing an Immune Response in Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents such as Short Interfering RNAs
Application Number: 20120045461
Filed: July 8, 2011
Lead Inventor: Gunther Hartmann, University Hospital Bonn
The invention, the patent application's abstract states, comprises “oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.”
Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-221
Application Number: 20120046192
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”
Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-222
Application Number: 20120046193
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”
Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-146a
Application Number: 20120046194
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”
Title: Multi-Targeting Short Interfering RNAs
Application Number: 20120046343
Filed: Nov. 2, 2011
Lead Inventor: John Rossi, City of Hope
The invention, the patent application's abstract states, “relates to novel short interfering RNA molecules that are multi-targeted. More specifically, the ... invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of microRNA molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets.”
Title: Down-Regulation of the Gene Expression by Means of Nucleic Acid-Loaded Virus-Like Particles
Application Number: 20120046340
Filed: Sept. 12, 2008
Lead Inventor: Jens Gruber, German Primate Center
The invention relates to “compositions of virus-like particles for the introduction of RNA interference-inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules,” the patent application's abstract states. The invention also relates to “methods for a diagnosis, prevention, and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids.”
Title: Lipid-Containing Formulations
Application Number: 20120046478
Filed: Aug. 16, 2011
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
The invention, the patent application's abstract states, comprises “compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes.”